Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | US$725.92B | 65.5x | 0.81 | US$808.61 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.2% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | US$373.57B | 17.1x | -0.42 | US$155.26 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.9% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | US$353.91B | 22x | 1.23 | US$78.73 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.9% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | US$337.52B | 81.6x | -2.65 | US$191.50 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.2% Upside | Upgrade to Pro+ | |
UnitedHealth | NYSE | Healthcare | Healthcare Providers & Services | US$281.72B | 12.8x | 0.28 | US$310.56 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.3% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | US$264.66B | 27.8x | -0.94 | US$328.52 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | US$264.66B | 27.8x | -0.94 | US$41.09 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
Abbott Labs | NYSE | Healthcare | Healthcare Equipment & Supplies | US$234.46B | 17.4x | 0.12 | US$135.28 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.7% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | US$232.18B | 18.4x | -1.36 | US$118 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | US$232.18B | 18.4x | -1.36 | US$118.07 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -7.2% Downside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | US$229.84B | 29.5x | 1.29 | US$148.21 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | US$229.84B | 29.5x | 1.29 | US$73.74 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.7% Upside | Upgrade to Pro+ | |
Merck&Co | NYSE | Healthcare | Pharmaceuticals | US$201.03B | 11.6x | 0.02 | US$80.32 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.3% Upside | Upgrade to Pro+ | |
Intuitive Surgical | NASDAQ | Healthcare | Healthcare Equipment & Supplies | US$187.24B | 75.4x | 3.29 | US$522.41 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10% Upside | Upgrade to Pro+ | |
Thermo Fisher Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$156.72B | 24.3x | 2.56 | US$415.15 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.1% Upside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | US$156.71B | 26.5x | 0.47 | US$291.81 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.2% Upside | Upgrade to Pro+ | |
Boston Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$146.89B | 72x | 4.75 | US$99.40 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.8% Upside | Upgrade to Pro+ | |
Danaher | NYSE | Healthcare | Healthcare Equipment & Supplies | US$146.51B | 39.4x | -3.06 | US$204.72 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.9% Upside | Upgrade to Pro+ | |
Stryker | NYSE | Healthcare | Healthcare Equipment & Supplies | US$145.64B | 50.8x | -3.32 | US$381.08 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | US$138.84B | 17.5x | 0.01 | US$24.48 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.2% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | US$135.68B | 23x | 0.02 | US$109.30 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.4% Upside | Upgrade to Pro+ | |
Essilor International SA | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$132.48B | 48.1x | 49.95 | US$143.07 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.6% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | US$121.34B | 17.4x | 0.43 | US$49.70 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.3% Upside | Upgrade to Pro+ | |
Vertex | NASDAQ | Healthcare | Pharmaceuticals | US$116.06B | -112.4x | 0.94 | US$452.44 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
Medtronic | NYSE | Healthcare | Healthcare Equipment & Supplies | US$112.89B | 24.3x | 0.79 | US$88.06 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | US$102.08B | 18.8x | 0.1 | US$50.16 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.1% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | US$89.63B | 27.6x | 1.8 | US$717.76 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.2% Upside | Upgrade to Pro+ | |
HCA | NYSE | Healthcare | Healthcare Providers & Services | US$87.79B | 16.2x | 1.24 | US$367.59 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.2% Upside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$86.35B | 30.3x | 1.2 | US$26.55 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Elevance Health | NYSE | Healthcare | Healthcare Providers & Services | US$86.07B | 14.8x | -4.56 | US$380.93 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.1% Upside | Upgrade to Pro+ | |
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | US$83.71B | 19.8x | -0.64 | US$41.62 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.1% Downside | Upgrade to Pro+ | |
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | US$83.71B | 19.8x | -0.64 | US$21 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CVS Health Corp | NYSE | Healthcare | Healthcare Providers & Services | US$83.14B | 15.6x | -0.58 | US$65.72 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.5% Upside | Upgrade to Pro+ | |
Cigna | NYSE | Healthcare | Healthcare Providers & Services | US$82.87B | 17x | 0.36 | US$310.20 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.4% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | US$76.23B | 27.6x | 2.51 | US$78.38 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.5% Upside | Upgrade to Pro+ | |
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | US$74.05B | 29.7x | 4.04 | US$166.33 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.7% Upside | Upgrade to Pro+ | |
Siemens Healthineers ADR | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$59.80B | 26.4x | US$26.58 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | US$58.05B | 17.9x | 5.17 | US$26.54 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32% Upside | Upgrade to Pro+ | |
Cencora Inc | NYSE | Healthcare | Healthcare Equipment & Supplies | US$55.56B | 33.1x | -5.44 | US$286.64 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.4% Upside | Upgrade to Pro+ | |
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$54.80B | 12.4x | 0.75 | US$518.60 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.8% Upside | Upgrade to Pro+ | |
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | US$49.90B | 58x | US$70.14 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.5% Upside | Upgrade to Pro+ | ||
Becton Dickinson | NYSE | Healthcare | Healthcare Equipment & Supplies | US$49.47B | 33.2x | 2.37 | US$172.72 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.4% Upside | Upgrade to Pro+ | |
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | US$48.65B | 25x | 0.64 | US$10.91 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.5% Upside | Upgrade to Pro+ | |
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | US$47.32B | 63.8x | -2.41 | US$15.17 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.9% Upside | Upgrade to Pro+ | |
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | US$47.32B | 63.8x | -2.41 | US$27.91 | -5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Veeva Systems A | NYSE | Healthcare | Healthcare Equipment & Supplies | US$47.12B | 59.9x | 1.53 | US$288.55 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.2% Upside | Upgrade to Pro+ | |
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | US$46.37B | 22.9x | 0.47 | US$24.95 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alcon | NYSE | Healthcare | Healthcare Equipment & Supplies | US$44.55B | 39.2x | 5.9 | US$88.58 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.3% Upside | Upgrade to Pro+ | |
Edwards Lifesciences | NYSE | Healthcare | Healthcare Equipment & Supplies | US$44.23B | 31.2x | 0.15 | US$75.47 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.5% Upside | Upgrade to Pro+ | |
IDEXX Labs | NASDAQ | Healthcare | Healthcare Equipment & Supplies | US$42.11B | 47.9x | 9.85 | US$524.18 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.6% Downside | Upgrade to Pro+ |